Consultancy to Develop the Climate-Smart Pharmaceutical Supply Chain Report and Investment Case Procurement Ref: 060/AUDA/HCID/AHSMI/IC/2026

Consultancy to Develop the Climate-Smart Pharmaceutical Supply Chain Report and Investment Case

Procurement Ref: 060/AUDA/HCID/AHSMI/IC/2026

Interested consultants may obtain further information from the address listed below. All Expressions of Interest should be sent electronically to the email listed below. Expressions of interest must be delivered to the address below by email on or before November 24, 2026, at 14:00 hours (South African Time). All EOI’s must be marked “060/AUDA/HCID/060/AUDA/HCID/AHSMI/IC/2026- Consultancy to Develop the Climate-Smart Pharmaceutical Supply Chain Report and Investment Case’’ in the subject line of the email. Privacy Policy: AUDA-NEPAD Procurement office collects and uses your personal information for “Procurement Process” when you intend to compete and deliver any service or goods for the organization either individually or as a firm based on your consent. Your personal data is our highest security and kept for a period strictly necessary for the purpose set out. This privacy notice supplements the AUDA-NEPAD standard privacy notice and should be read in conjunction with the same available on AUDA-NEPAD website. The Chairperson Internal Procurement Committee (IPC) AUDA-NEPAD Block F, Eco Origin Office Park, 349 Witch-Hazel Avenue, Eco-Park Estate, Highveld, Centurion, South Africa

Email: procurement@nepad.org & copy edigaro@auda-nepad.org

Attention of: Head of Procurement Division

Documents: Download File; Download File

— From AHSMI ToR_Climate Smart Supply Chain Report Advert copy.pdf — 1 | P a g e Block F, Eco Origin Office Park, 349 Witch -Hazel Avenue, Eco -Park Estate, Highveld, Centurion, Gauteng, South Africa, 0144 OFFICE - [contact details removed] | FAX: [contact details removed] | WEB - www.nepad.org

TERMS OF REFERENCE

Title of the Consultancy Consultancy to Develop the Climate-Smart Pharmaceutical Supply Chain Report and Investment Case

Consultancy type (Individual or firm) Individual Directorate & Division Human Capital and Institutional Development (HCID) Procurement Number (from procurement plan) 060/AUDA/HCID/AHSMI/IC/2026

Background The African Union Development Agency -NEPAD (AUDA -NEPAD), in

partnership with UNITAID, is implementing the African Health Security

Manufacturing Initiative (AHSMI), an initiative to accelerate a resilient African pharmaceutical manufacturing sector, with an initial focus on maternal and newborn health. Africa still imports most of its medicines and almost all of its vaccines, which exposes the continent to supply shocks and constrains access to quality-assured products. AHSMI responds through three pillars: improving coordination between ecosystem actors; building a coherent, data-driven ecosystem; and future -proofing the sector through integrated agendas, including climate resilience. This consultancy delivers a core product under the third pillar. Climate change threatens pharmaceutical supply chains on both sides. Rising temperatures, extreme weather, water scarcity and unstable power disrupt manufacturing, break the cold chain, interrupt raw -material supply and degrade distribution. Pharmaceutical production is itself energy - intensive and a source of emissions and waste. Climate -smart approaches including energy efficiency, renewable energy, waste reduction and circular- economy models, are therefore both an environmental necessity and a commercial opportunity. At the continental level, the African Union Climate Change and Resilient Development Strategy and Action Plan (2022 –2032), the AU Green Recovery Action Plan and the industrialisation priorities of Agenda 2063 set the policy direction, alongside the Pharmac eutical Manufacturing Plan for Africa and the 24 Priority Medical Products Roadmap. Environmental, social and governance (ESG) expectations now shape how development finance institutions and private investors assess pharmaceutical assets, thus the environmental performance of a plant becomes a financing question. Through its Regional Indus

— From REOI Climate Smart Supply Chain Report.pdf — REQUEST FOR EXPRESSIONS OF INTEREST (REOI) FOR INDIVIDUAL CONSULTANTS

Title: Consultancy to Develop the Climate -Smart Pharmaceutical Supply Chain Report and

Investment Case

Procurement Ref: 060/AUDA/HCID/AHSMI/IC/2026

Method: Individual Consultants Selection (ICS) - Individuals Only

1.0 BACKGROUND

The African Union Development Agency-NEPAD (AUDA-NEPAD), in partnership with UNITAID, is implementing the African Health Security Manufacturing Initiative (AHSMI), an initiative to accelerate a resilient African pharmaceutical manufacturing sector, with an initial focus on maternal and newborn health. Africa still imports most of its medicines and almost all of its vaccines, which exposes the continent to supply shocks and constrains access to quality-assured products. AHSMI

responds through three pillars: improving coordination between ecosystem actors; building a

coherent, data -driven ecosystem; and future -proofing the sector through integrated agendas, including climate resilience. This consultancy delivers a core product under the third pillar.

Climate change threatens pharmaceutical supply chains on both sides. Rising temperatures, extreme weather, water scarcity and unstable power disrupt manufacturing, break the cold chain, interrupt raw-material supply and degrade distribution. Pharmaceutical production is itself energy- intensive and a source of emissions and waste. Climate -smart approaches including energy efficiency, renewable energy, waste reduction and circular-economy models, are therefore both an environmental necessity and a commercial opportunity.

At the continental level, the African Union Climate Change and Resilient Development Strategy and Action Plan (2022 –2032), the AU Green Recovery Action Plan and the industrialisation priorities of Agenda 2063 set the policy direction, alongside the Pharmaceutical Manufacturing Plan for Africa and the 24 Priority Medical Products Roadmap. Environmental, social and governance (ESG) expectations now shape how development finance institutions and private investors assess pharmaceutical assets, thus the environm ental performance of a plant becomes a financing question.

Through its Regional Industrialization Policy (2015–2030), its Industrial Strategy (2017–2026) and a Regional Pharmaceutical Sector Development Initiative, COMESA has developed an Environmental and Social Safeguards Framework for the pharmaceutical industr y (validated in Kigali, July 2024)

Published by AUDA-NEPAD (African Union Development Agency). Submission instructions and deadlines are in the attached documents; the notice is listed at https://www.nepad.org/tenders.